Brief: Bioplus Acquisition Corp. Announces Termination Of Business Combination Agreement With Avertix Medical
04/10/2023 12:35
Oct 4 (Reuters) - BioPlus Acquisition Corp BIOS.O :
* BIOPLUS ACQUISITION CORP. ANNOUNCES TERMINATION OF
BUSINESS
COMBINATION AGREEMENT WITH AVERTIX MEDICAL, INC. AND ITS
INTENTION TO LIQUIDATE
* BIOPLUS ACQUISITION CORP. ANNOUNCES TERMINATION OF
BUSINESS
COMBINATION AGREEMENT WITH AVERTIX MEDICAL, INC. AND ITS
INTENTION TO LIQUIDATE
* BIOPLUS ACQUISITION CORP - EXPECTS TO REDEEM ALL OF ITS
PUBLIC
SHARES FOR AN ESTIMATED REDEMPTION PRICE OF APPROXIMATELY $10.79
PER SHARE
* BIOPLUS ACQUISITION CORP - REDEMPTION OF PUBLIC SHARES IS
EXPECTED TO BE COMPLETED WITHIN TEN BUSINESS DAYS AFTER OCTOBER
4, 2023
Source text for Eikon: ID:nGNX8yPvfD
Further company coverage: BIOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioPlus Acquisition
See all newsBrief: Avertix And Bios Acquisition Corporation Mutually Agree To Terminate Proposed Business Combination
Brief: Bioplus Acquisition Corp. Announces Termination Of Business Combination Agreement With Avertix Medical
Brief: Avertix To Become Publicly Traded Via Merger With Bios Acquisition Corp
Brief: BioPlus Acquisition Says Ceased Use Of Its Name In Marketing & Public Materials, Other Than When Use Of Co's Legal Name Is Needed In Certain Documents
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM